

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Ashkenazi, et al.

Docket No.:

39780-2730P1C26

09/997,542

Group Art Unit:

1647

Filing Date:

November 15, 2001

Examiner:

Landsman, Robert S.

For:

PRO1281 ANTIBODIES

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

	This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):						
		(1)	It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d) OR				
		(2)	It is being filed within 3 months of entry of a national stage OR				
			CERTIFICATE OF MAILING (37 CFR 1.10(a))				
with the U	U.S. Posta	al Service "	EXPRESS MAIL" - Rule 10: I hereby certify that this correspondence is being deposited on June 4, 2004 Express Mail Post Office to Addressee" under 37 CFR 1.10 as Express Mail No. EL 993 688 403 US addressed nissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.				
Date: June 4, 2004 Cheryl Ann Rogers							
HUUINNG1	0000005	7 081641	()				

06/08/2004 HVUONG1 00000057 081641 09997548

01 FC:1806

180.00 DA

180

180.00

PTO/SB/17 (10-03 Approved for use through 07/31/2006. OMB 0651-0032 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under May Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number							
MOEMARY CEE TO A NICHAITTA							
FEE TRANSMITTA	ᄕ	Applic	cation Numbe	r 09/997,542	09/997,542		
for FY 2004	ſ	Filing Date		November 15, 2001	November 15, 2001		
Effective 1010112003. Patent fees are subject to ennual revision.		First Named Inventor		or Ashkenazi, et al.	Ashkenazi, et al.		
				Landsman, Robert S.			
Applicant claims small entity status. See 37 CFR 1.27		Art U	nit	1647	1647		
TOTAL AMOUNT OF PAYMENT (\$) 180.00		Attorr	ney Docket No	39780-2730P1C26			
METHOD OF PAYMENT (check all that apply)		FEE CALCULATION (continued)					
Check Credit card Money Other None Deposit Account: Deposit Account Number Deposit Account HELLER EHRMAN WHITE & McAULIFFE LLP Name The Director Is authorized to: (check all that apply) Charge fee(s) indicated below Charge any additional fee(s) or any underpayment of fee(s) Charge fee(s) indicated below, except for the filing fee	Large Fee Code 1051 1052 1053 1812 1804	Fee (\$) 130 50 130 2,520	2052 25 S 1053 130 M 1812 2,520 F 1804 920* F	Fee Description	ee Paid		
to the above-identified deposit account.	1251	110		Examiner action Extension for reply within first month			
FEE CALCULATION	1252	420		Extension for reply within second month			
1. BASIC FILING FEE Large Entity Small Entity Fee Fee Fee Fee Fee Description Code (\$) Code (\$) 1001 770 2001 385 Utility filing fee	1253 1254		2253 475 2254 740	Extension for reply within third month Extension for reply within fourth month Extension for reply within fifth month			

1401

1402

1403

1451 1,510

330

330

290

2401

2402

2403

165 Notice of Appeal

145 Request for oral hearing

165 Filing a brief in support of an appeal

1451 1,510 Petition to institute a public use proceeding

SUBTOTAL (3)

SUBTOTAL (1) (\$)	1452 110	2452 55 Petition to revive - unavoidable		
	1453 1,330	2453 665 Petition to revive - unintentional		
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE	1501 1,330	2501 665 Utility issue fee (or reissue)		
Extra Claims below Fee Paid	1502 480	2502 240 Design issue fee		
Total Claims20** = X =	1503 640	2503 320 Plant issue fee		
Independent - 3** = X = X	1460 130	1460 130 Petitions to the Commissioner		
Multiple Dependent	1807 50	1807 50 Processing fee under 37 CFR 1.17(q)		
Large Entity Small Entity	1806 180	1806 180 Submission of Information Disclosure Stmt		
Fee Fee Fee Fee Fee Description Code (\$)	8021 40	8021 40 Recording each patent assignment per property (times number of properties)		
1202 18 2202 g Claims in excess of 20	1809 770	2809 385 Filing a submission after final rejection		
1201 86 2201 43 Independent claims in excess of 3		(37 ČFR 1.129(a))		
1203 290 2203 145 Multiple dependent claim, if not paid	1810 770	2810 385 For each additional invention to be examined (37 CFR 1.129(b))		
1204 86 2204 43 ** Reissue independent claims over original patent	1801 770	2801 385 Request for Continued Examination (RCE)		
1205 18 2205 9 ** Reissue claims in excess of 20 and over original patent	1802 900	1802 900 Request for expedited examination of a design application		
SUBTOTAL (2) (\$)	Other fee (specify)			

1002 340

1003 530

1004 770

1005 160

2002 170

2003 265

2004 385

2005 80 Design filing fee

Reissue filing fee

Provisional filing fee

Plant filing fee

SUBTOTAL (2)

**or number previously paid, if greater; For Reissues, see above

(\$)

SUBMITTED BY		(Complete (if applicable))					
Name (Print/Type)	Daphne Reddy	Registration No. (Attorney/Agent) 53,507	Telephone (650) 324-7000				
Signature	Saphere Reddy		Dete	June 4, 2004			

*Reduced by Basic Filing Fee Paid

WARNING: information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

	Ш	(3)	It is being filed before OR	the mail date	of the first Office Action on the merits			
		(4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.						
	37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:							
		a certifi	ication as specified in §	1.97(e) is pro	ovided below; or			
	\boxtimes	a fee of \$180.00 as set forth in \$1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.						
	office a	37 C.F.R. $\S1.97(d)$. If this statement is being filed after the mailing date of the earlier of a final office action under $\S1.113$ or a notice of allowance under $\S1.311$, but before payment of the issue fee, then:						
	A.	a certifi	ication as specified in §	1.97(e) is con	mpleted below; and			
	В.		on under 37 C.F.R. §1.9 ted herewith; and	7(d) requesting	ng consideration of this statement is			
	C.	a fee of \$180.00 as set forth in \$1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.						
\boxtimes	Fee Authorization. The Commissioner is hereby authorized to charge the above-referenced fees of \$180.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. <u>08-1641 (Docket No. 39780-2730P1C26)</u> .							
				Res	spectfully submitted,			
Dated:	June 4,	2004	•	By	Daphne Reddy			
					Reg. No. 53,507			

HELLER EHRMAN WHITE & MCAULIFFE LLP

Customer No. 35489
275 Middlefield Road
Menlo Park, CA 94025-3506
Telephone: (650) 324-7000
Facsimile: (650) 324-0638

	ATION DISCLO	OSURE	ATTY. DOCKET NO.:		SERIAL NO.:					
OIPSTATEMENT			39780-2730P1C26 09/997,542							
	**************************************		APPLICANT: Ashkenazi, et al.							
JUN 0 4 200 FRADEMARYS EXAMINER'S	35		FILING DATE: 11/15/01	GR	GROUP: 1647					
RADEMARK		U.S.	PATENT DOCUMENTS							
EXAMINER'S INITIALS			NAME CLAS		SUBCLASS FILING DAT		DATE			
		FOR	EIGN PATENT DOCUMENTS			,	<u>.</u>			
EXAMINER'S	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION				
INITIALS						YES	NO			
	OTHER DO	CUMENTS (Including Author, Title, Date, Pe	rtinent Pa	ges, Etc.)					
	Dayhoff, Accession	No.: P_AAI	365252, WO200073454-A1, Pub. D	Date: Dec. 7	7, 2000, Ashken	azi, A.J.	et al.			
	Dayhoff, Accession No.: P_AAY66729, WO9963088-A2, Pub. Date: Dec. 9, 1999, Baker, K. et. al.									
	Dayhoff, Accession No.: P_AAB24078, WO200053755-A2, Pub. Date: Sept. 14, 2000, Ashkenazi, A.J. et.al.									
	Dayhoff, Accession	No.: P_AAY	766729, WO9963088-A2, Pub. Dat	e: Dec. 9,	1999, Baker, K.	et.al.				
	Dayhoff, Accession No.: P_AAM39781, WO200153312-A1, Pub. Date: July 26, 2001, Tang, YT et. al.									
	Dayhoff, Accession	No.: CAB66	5748.1, Direct Submission, Submitt	ed: July 9,	2002, Blum, H.	et al.				
	GenBank, Accession No.: P_AAZ65074, WO9963088-A2, Pub. Date: Dec. 9, 1999, Baker, K. et.al.									
	GenBank, Accession No.: P_AAF44220, WO200073454-A1, Pub. Date: Dec. 7, 2000, Ashkenazi, A.J. et.al.									
	GenBank, Accessio	n No.: P_AA	.C58388, WO200053755-A2, Pub.	Date: Sept.	14, 2000, Ashk	enazi, A	J. et.al.			
	GenBank, Accession No.: P_AAC69800, WO200052165-A2, Pub. Date: Sept. 8, 2000, Lodes, M.J.									
	Hanna, Julie S., et al., "HER-2/neu Breast Cancer Predictive Testing", Pathology Associates Medical Laboratories Technical Update (1999).									
	Hyman, Elizabeth, et al., "Impact of DNA Amplification on Gene Expression Patterns in Breast Cancer", Cancer Research 62; pp. 6240-6245, (2002).									
	Orntoft, Torben F., et al., "Genome-wide Study of Gene Copy Numbers, Transcripts, and Protein Levels in Pairs of Non-invasive and Invasive Human Transitional Cell Carcinomas" <i>Molecular & Cellular Proteomics</i> 1.1; pp. 37-45, (2001).									
	Pollack, Jonathan R., et al., "Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors", PNAS, Vol. 99, No. 20; pp. 12963-12968 (2002).									
EYAMINED			DATE CONSIDERED							

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.